OncoMatch

OncoMatch/Clinical Trials/NCT06728072

Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer

Is NCT06728072 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin for colorectal cancer.

Phase 2RecruitingVirginia Commonwealth UniversityNCT06728072Data as of Jun 2026

Treatment: Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirinThis is a 2-arm, noncomparative phase 2 trial designed to evaluate treatment outcomes with or without the addition of ciprofloxacin, metronidazole, and aspirin to first-line chemotherapy for patients with stage IV colorectal cancer (CRC).

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

Standard of Care Chemotherapy + Metronidazole, ciprofloxacin, aspirin

Cancer type

Colorectal Cancer

Disease stage

Required: Stage IV

Metastatic disease required

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: antibiotics

Exception: prophylactic antibiotics at time of surgery allowed

Full course of antibiotics in the 30 days before chemotherapy start Note: Full course is defined as ≥5 doses with an intent to treat a defined infection. Use of antibiotics intended for prophylaxis at the time of surgery is allowed

Lab requirements

Blood counts

ANC ≥1,500 cells/μL; Platelet count ≥100,000 cells/μL; Hemoglobin ≥8 g/dL (transfusion/intervention allowed to achieve threshold)

Kidney function

Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥40 mL/min using the Cockcroft-Gault equation

Liver function

AST and ALT ≤2.5 × ULN; if liver metastases: AST and ALT ≤5 × ULN

Cardiac function

Corrected QT interval (QTc) ≤480 on baseline ECG

ANC ≥1,500 cells/μL; Platelet count ≥100,000 cells/μL; Hemoglobin ≥8 g/dL Note: The use of transfusion or other intervention to achieve hemoglobin ≥8 g/dL is acceptable. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × upper limit of normal (ULN) Note: Patients with documented liver metastases: AST and ALT ≤5 × ULN; Serum creatinine ≤1.5 x ULN or calculated creatinine clearance ≥40 mL/min using the Cockcroft-Gault equation; Corrected QT interval (QTc) >480 on baseline ECG [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Virginia Commonwealth University · Richmond, Virginia

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT06728072 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage IV is required (metastatic disease required).

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify